Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered MWX205 Injection in Adult Participants With Dyslipidemia

NCT07634510 is registered in ClinicalTrials.gov with Shanghai Minwei Biotechnology Co., Ltd as lead sponsor.

NCT NCT07634510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07634510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered MWX205 Injection in Adult Participants With Dyslipidemia
Lead sponsor
Shanghai Minwei Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 22, 2026
Completion date
November 8, 2027
Enrollment
37 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias